Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pathologic diagnosis of colorectal cancer.~2. A minimum of 1 unresectable mCRC liver lesion at baseline clinically indicated for radiofrequency ablation (RFA) or microwave ablation (MWA).~   * Recurrent lesions may have been treated previously by resection or ablation.~  * Anticipated ablation volume will be no larger than either removal of 3 hepatic segments or removal of more than 30% of total liver volume (as per maximum surgical limit).~  * Patients may have resectable lesions that are treated surgically.~  * If additional lesions are discovered during the ablation treatment procedure that were undetectable at screening will be treated at the discretion of the physician and guided by local standard of care.~  * Confirm the lesions are malignant by a pretreatment biopsy or by a biopsy obtained during the ablation procedure.~3. Subjects with suspected or limited extra-hepatic mCRC are eligible provided thermal ablation is clinically indicated. Chemotherapy is not permitted within 5 half-lives or 30 days if shorter prior to initial study treatment through 30 days following final study treatment.~4. Male or female 18 years of age or older.~5. Are willing to sign an informed consent form.~6. Left Ventricular Ejection Fraction(LVEF) ≥ 50%~7. Willing to return to the study site for study visits.~8. Have ECOG performance status ≤ 2 and life expectancy of ≥ 6 months.~Exclusion Criteria:~1. Concomitant bowel surgery and/or synchronous colon resection.~2. Have serious illnesses including, but not limited to, congestive heart failure;life threatening cardiac arrhythmia; or myocardial infarction or cerebral vascular accident within the last 6 months.~3. Have previously received any doxorubicin (study subjects being considered for completion of treatment may have received ThermoDox previously).~4. Are pregnant or breast-feeding. In women of childbearing potential, a negative pregnancy test (serum) is required within 14 days prior to study treatment.~5. Women and men of childbearing potential who are not practicing an acceptable form of birth control (i.e. diaphragm, cervical cap, condom, surgical sterility or birth control pills.~6. Have any known allergic reactions to any of the drugs or liposomal components or intravenous imaging agents to be used in this study.~7. Have portal or hepatic vein tumor invasion/thrombosis.~8. Have INR \> 1.5 times the institution's upper normal limit (UNL), except in subjects who are therapeutically anticoagulated for medical conditions unrelated to CRLM such as atrial fibrillation. Subjects may be re-screened after condition is treated or anticoagulant is withheld.~9. Have platelet count \< 75,000/mm3, absolute neutrophil count \< 1500/mm3, or Hgb \< 10.0 g/dL (unless the hemoglobin value has been stable, the subject is cardiovascularly stable, asymptomatic, and judged able to withstand the RFA procedure).~10. Have serum creatinine ≥ 2.5 mg/dL or calculated creatinine clearance (CrCl) ≤ 25.0 mL/min.~11. Have serum bilirubin \> 3.0 mg/dL.~12. Have serum albumin \< 2.8 g/dL.~13. Have body temperature \> 38.3°C immediately prior to study treatment.~14. Have contraindications to receiving doxorubicin HCl.~15. Are being treated with other investigational agents or use of an investigational agent within 5 half-lives or 30 days whichever is longer preceding the first dose of study medication.~16. Use of chemotherapy within 5 half-lives or 30 days, whichever is shorter, preceding the first dose of study medication and no chemotherapy planned for 30 days after ablation(s).~17. Have concurrent malignancy other than mCRC (subjects wtih treated squamous cell carcinoma of the skin or basal cell carcinoma of the skin maybe included) or ongoing medically significant active infection.~18. Documented HIV positive.~19. NYHA class III or IV functional classification for heart failure.~20. Evidence of hemochromatosis.~21. Have history of contrast induced nephropathy and unable to undergo MRI.~22. Have a history of Nephrogenic Systemic Fibrosis (NSF).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thermodox (Type: EXPERIMENTAL): Thermodox 50 mg/m2 intravenous infusion over 30 minutes starting 15 minutes before thermal ablation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues